 INTRODUCTION Neovascular age-related macular degeneration nAMD is one of the most common disorders that cause irreversible blindness in the senior population in the developed world. If left untreated the patients may experience gradual central visual impairment and metamorphopsia which could severely affect their quality of life. However, with the development and application of intravitreal injection of anti-vascular endothelial growth factor VEGF, the visual prognosis of nAMD has been greatly improved.Currently there are three commonly prescribed anti-VEGF agents. Aflibercept Eylea; Regeneron Pharma, Tarrytown, New York, USA; Bayer, Basel, Switzerland, ranibizumab Lucentis; Novartis Pharma, Basel, Switzerland; Genentech, South San Francisco, Chicago, USA, and bevacizumab Avastin; Genentech. Generally speaking, the binding affinity of VEGF is stronger in aflibercept than in ranibizumab and bevacizumab. Previous studies have shown that aflibercept may be effective in eyes resistant to ranibizumab or bevacizumab. 